Your browser doesn't support javascript.
loading
PROMISE: a real-world clinical-genomic database to address knowledge gaps in prostate cancer.
Koshkin, Vadim S; Patel, Vaibhav G; Ali, Alicia; Bilen, Mehmet A; Ravindranathan, Deepak; Park, Joseph J; Kellezi, Olesia; Cieslik, Marcin; Shaya, Justin; Cabal, Angelo; Brown, Landon; Labriola, Matthew; Graham, Laura S; Pritchard, Colin; Tripathi, Abhishek; Nusrat, Sanober; Barata, Pedro; Jang, Albert; Chen, Shuang R; Garje, Rohan; Acharya, Luna; Hwang, Clara; Pilling, Amanda; Oh, William; Jun, Tomi; Natesan, Divya; Nguyen, Chris; Kilari, Deepak; Pierro, Michael; Thapa, Bicky; Cackowski, Frank; Mack, Alleda; Heath, Elisabeth; Marshall, Catherine H; Tagawa, Scott T; Halabi, Susan; Schweizer, Michael T; Armstrong, Andrew; Dorff, Tanya; Alva, Ajjai; McKay, Rana.
Afiliación
  • Koshkin VS; Division of Hematology and Oncology, Department of Medicine, University of California San Francisco, San Francisco, CA, USA.
  • Patel VG; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Ali A; Division of Hematology and Oncology, Department of Medicine, University of Michigan, Ann Arbor, MI, USA.
  • Bilen MA; Winship Cancer Institute of Emory University, Atlanta, GA, USA.
  • Ravindranathan D; Winship Cancer Institute of Emory University, Atlanta, GA, USA.
  • Park JJ; Division of Hematology and Oncology, Department of Medicine, University of Michigan, Ann Arbor, MI, USA.
  • Kellezi O; Division of Hematology and Oncology, Department of Medicine, University of Michigan, Ann Arbor, MI, USA.
  • Cieslik M; Division of Hematology and Oncology, Department of Medicine, University of Michigan, Ann Arbor, MI, USA.
  • Shaya J; Moores Cancer Center, University of California San Diego Health, La Jolla, CA, USA.
  • Cabal A; Moores Cancer Center, University of California San Diego Health, La Jolla, CA, USA.
  • Brown L; Duke Cancer Institute Center for Prostate and Urologic Cancers, Durham, NC, USA.
  • Labriola M; Duke Cancer Institute Center for Prostate and Urologic Cancers, Durham, NC, USA.
  • Graham LS; Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Pritchard C; Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Tripathi A; Stephenson Cancer Center, Oklahoma City, OK, USA.
  • Nusrat S; Stephenson Cancer Center, Oklahoma City, OK, USA.
  • Barata P; Tulane Cancer Center, Tulane University, New Orleans, LA, USA.
  • Jang A; Tulane Cancer Center, Tulane University, New Orleans, LA, USA.
  • Chen SR; Tulane Cancer Center, Tulane University, New Orleans, LA, USA.
  • Garje R; Holden Comprehensive Cancer Center, Iowa City, IA, USA.
  • Acharya L; Holden Comprehensive Cancer Center, Iowa City, IA, USA.
  • Hwang C; Division of Hematology/Oncology, Department of Internal Medicine, Henry Ford Health System, Detroit, MI, USA.
  • Pilling A; Division of Hematology/Oncology, Department of Internal Medicine, Henry Ford Health System, Detroit, MI, USA.
  • Oh W; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Jun T; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Natesan D; Division of Hematology and Oncology, Department of Medicine, University of California San Francisco, San Francisco, CA, USA.
  • Nguyen C; Division of Hematology and Oncology, Department of Medicine, University of California San Francisco, San Francisco, CA, USA.
  • Kilari D; Department of Medicine, Medical College of Wisconsin Cancer Center, Medical College of Wisconsin, Milwaukee, WI, USA.
  • Pierro M; Department of Medicine, Medical College of Wisconsin Cancer Center, Medical College of Wisconsin, Milwaukee, WI, USA.
  • Thapa B; Department of Medicine, Medical College of Wisconsin Cancer Center, Medical College of Wisconsin, Milwaukee, WI, USA.
  • Cackowski F; Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA.
  • Mack A; Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA.
  • Heath E; Karmanos Cancer Institute, Wayne State University, Detroit, MI, USA.
  • Marshall CH; Johns Hopkins Sidney Kimmel Cancer Center, Johns Hopkins University, Baltimore, MD, USA.
  • Tagawa ST; Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA.
  • Halabi S; Duke Cancer Institute Center for Prostate and Urologic Cancers, Durham, NC, USA.
  • Schweizer MT; Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Armstrong A; Duke Cancer Institute Center for Prostate and Urologic Cancers, Durham, NC, USA.
  • Dorff T; Department of Medical Oncology & Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
  • Alva A; Division of Hematology and Oncology, Department of Medicine, University of Michigan, Ann Arbor, MI, USA.
  • McKay R; Moores Cancer Center, University of California San Diego Health, La Jolla, CA, USA. rmckay@health.ucsd.edu.
Prostate Cancer Prostatic Dis ; 25(3): 388-396, 2022 09.
Article en En | MEDLINE | ID: mdl-34363009
ABSTRACT

PURPOSE:

Prostate cancer is a heterogeneous disease with variable clinical outcomes. Despite numerous recent approvals of novel therapies, castration-resistant prostate cancer remains lethal. A "real-world" clinical-genomic database is urgently needed to enhance our characterization of advanced prostate cancer and further enable precision oncology.

METHODS:

The Prostate Cancer Precision Medicine Multi-Institutional Collaborative Effort (PROMISE) is a consortium whose aims are to establish a repository of de-identified clinical and genomic patient data that are linked to patient outcomes. The consortium structure includes a (1) bio-informatics committee to standardize genomic data and provide quality control, (2) biostatistics committee to independently perform statistical analyses, (3) executive committee to review and select proposals of relevant questions for the consortium to address, (4) diversity/inclusion committee to address important clinical questions pertaining to racial disparities, and (5) patient advocacy committee to understand patient perspectives to improve patients' quality of care.

RESULTS:

The PROMISE consortium was formed by 16 academic institutions in early 2020 and a secure RedCap database was created. The first patient record was entered into the database in April 2020 and over 1000 records have been entered as of early 2021. Data entry is proceeding as planned with the goal to have over 2500 patient records by the end of 2021.

CONCLUSIONS:

The PROMISE consortium provides a powerful clinical-genomic platform to interrogate and address data gaps that have arisen with increased genomic testing in the clinical management of prostate cancer. The dataset incorporates data from patient populations that are often underrepresented in clinical trials, generates new hypotheses to direct further research, and addresses important clinical questions that are otherwise difficult to investigate in prospective studies.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Próstata Tipo de estudio: Diagnostic_studies / Observational_studies / Prognostic_studies Límite: Humans / Male Idioma: En Revista: Prostate Cancer Prostatic Dis Asunto de la revista: ENDOCRINOLOGIA / NEOPLASIAS / UROLOGIA Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Próstata Tipo de estudio: Diagnostic_studies / Observational_studies / Prognostic_studies Límite: Humans / Male Idioma: En Revista: Prostate Cancer Prostatic Dis Asunto de la revista: ENDOCRINOLOGIA / NEOPLASIAS / UROLOGIA Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos